Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125217781 | 12521778 | 1 | I | 20160621 | 20160701 | 20160701 | EXP | DE-SA-2016SA120271 | AVENTIS | 88.00 | YR | E | F | Y | 48.00000 | KG | 20160701 | CN | DE | DE |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125217781 | 12521778 | 1 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | Y | UNK | 0 | 40 | MG | BID | ||||||
125217781 | 12521778 | 2 | SS | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | Oral | Y | UNK | 0 | 47.5 | MG | BID | ||||||
125217781 | 12521778 | 3 | SS | RAMIPRIL. | RAMIPRIL | 1 | Oral | Y | UNK | 0 | 5 | MG | BID | ||||||
125217781 | 12521778 | 4 | SS | CANDESARTAN CILEXETIL. | CANDESARTAN CILEXETIL | 1 | Oral | Y | UNK | 0 | 16 | MG | QD | ||||||
125217781 | 12521778 | 5 | SS | ISOSORBIDE DINITRATE. | ISOSORBIDE DINITRATE | 1 | Unknown | Y | UNK | 0 | 20 | MG | BID | ||||||
125217781 | 12521778 | 6 | SS | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | Y | UNK | 0 | 25 | MG | QD | ||||||
125217781 | 12521778 | 7 | SS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | Y | UNK | 0 | 850 | MG | BID | ||||||
125217781 | 12521778 | 8 | PS | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | Oral | Y | UNK | 20496 | 1 | MG | QD | ||||||
125217781 | 12521778 | 9 | SS | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | Y | UNK | 0 | 300 | MG | QD | ||||||
125217781 | 12521778 | 10 | SS | ESCITALOPRAM | ESCITALOPRAM OXALATE | 1 | Oral | Y | UNK | 0 | 20 | MG | QD | ||||||
125217781 | 12521778 | 11 | SS | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | Oral | Y | UNK | 0 | 40 | MG | QD | ||||||
125217781 | 12521778 | 12 | SS | NALOXONE HYDROCHLORIDE/TILIDINE PHOSPHATE | NALOXONE HYDROCHLORIDETILIDINE PHOSPHATE | 1 | Oral | 4/50 MG | Y | UNK | 0 | 1 | DF | TID | |||||
125217781 | 12521778 | 13 | SS | TROSPIUM | TROSPIUM | 1 | Oral | Y | UNK | 0 | 15 | MG | QD | ||||||
125217781 | 12521778 | 14 | SS | DIGITOXIN | DIGITOXIN | 1 | Unknown | Y | UNK | 0 | .07 | MG | QD | ||||||
125217781 | 12521778 | 15 | SS | INSULIN | INSULIN NOS | 1 | Unknown | 30/70 IU; AT A DOSE OF 26-0-16 IU | UNK | 0 | |||||||||
125217781 | 12521778 | 16 | SS | MOXONIDINE | MOXONIDINE | 1 | Oral | Y | UNK | 0 | .4 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125217781 | 12521778 | 1 | Product used for unknown indication |
125217781 | 12521778 | 2 | Product used for unknown indication |
125217781 | 12521778 | 3 | Product used for unknown indication |
125217781 | 12521778 | 4 | Product used for unknown indication |
125217781 | 12521778 | 5 | Product used for unknown indication |
125217781 | 12521778 | 6 | Product used for unknown indication |
125217781 | 12521778 | 7 | Product used for unknown indication |
125217781 | 12521778 | 8 | Product used for unknown indication |
125217781 | 12521778 | 9 | Blood uric acid increased |
125217781 | 12521778 | 10 | Product used for unknown indication |
125217781 | 12521778 | 11 | Product used for unknown indication |
125217781 | 12521778 | 12 | Product used for unknown indication |
125217781 | 12521778 | 13 | Product used for unknown indication |
125217781 | 12521778 | 14 | Product used for unknown indication |
125217781 | 12521778 | 15 | Diabetes mellitus |
125217781 | 12521778 | 16 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125217781 | 12521778 | DS |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125217781 | 12521778 | Abasia | |
125217781 | 12521778 | Asthenia | |
125217781 | 12521778 | Blood sodium decreased | |
125217781 | 12521778 | Cognitive disorder | |
125217781 | 12521778 | Decreased appetite | |
125217781 | 12521778 | Dysstasia | |
125217781 | 12521778 | General physical health deterioration | |
125217781 | 12521778 | Haemoglobin decreased | |
125217781 | 12521778 | Hypotension | |
125217781 | 12521778 | Impaired self-care | |
125217781 | 12521778 | Multiple drug therapy | |
125217781 | 12521778 | Somnolence | |
125217781 | 12521778 | Urinary incontinence | |
125217781 | 12521778 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |